Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 16

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 16
---
     |            |      74,756 |   |     |              |     79,756 |   |     |              |         - |   |
| Cash, restricted cash and cash equivalents                                     |     | $          |   3,302,674 |   |     | $            |  3,647,026 |   |     | $            |   963,855 |   |
| NON-CASH FINANCING ACTIVITIES:                                                 |     |            |             |   |     |              |            |   |     |              |           |   |
| Issuance of common shares to Keystone Capital LLC for equity line of credit    |     | $          |           - |   |     | $            |    250,000 |   |     | $            |         - |   |
| Issuance of common shares to Arena Investors LP for equity line of credit      |     | $          |           - |   |     | $            |    500,000 |   |     | $            |         - |   |
| Conversion of Series A, Series B and Series C Preferred Stock to common stock  |     | $          |   2,074,340 |   |     | $            |          - |   |     | $            |         - |   |
| Reclassification of deferred offering costs to additional paid-in capital      |     | $          |     112,232 |   |     | $            |          - |   |     | $            |         - |   |
| Reclassification of accrued expenses to accounts payable                       |     | $          |   1,143,826 |   |     | $            |          - |   |     | $            |         - |   |
| Issuance of Series D preferred stock for investment in equity securities       |     | $          |     500,000 |   |     | $            |          - |   |     | $            |         - |   |

<div align='center'>See accompanying notes to the condensed consolidated financial statements

5

CERO THERAPEUTICS HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2025

(Unaudited)</div>

NOTE 1 – ORGANIZATION AND DESCRIPTION OF THE BUSINESS

Nature of Operations –CERo Therapeutics Holdings, Inc. (NASDAQ: CERO